JP2020111586A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020111586A5 JP2020111586A5 JP2020042730A JP2020042730A JP2020111586A5 JP 2020111586 A5 JP2020111586 A5 JP 2020111586A5 JP 2020042730 A JP2020042730 A JP 2020042730A JP 2020042730 A JP2020042730 A JP 2020042730A JP 2020111586 A5 JP2020111586 A5 JP 2020111586A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- solvate
- salt
- induced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 13
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 206010067125 Liver injury Diseases 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 231100000439 acute liver injury Toxicity 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- -1 pentoxifyllines Substances 0.000 claims 2
- 229930186147 Cephalosporin Natural products 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 1
- 229940124587 cephalosporin Drugs 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229940124307 fluoroquinolone Drugs 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 231100000753 hepatic injury Toxicity 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 229940041033 macrolides Drugs 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 150000002960 penicillins Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 229940040944 tetracyclines Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562114304P | 2015-02-10 | 2015-02-10 | |
| US62/114,304 | 2015-02-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560462A Division JP6676660B2 (ja) | 2015-02-10 | 2015-09-22 | 線維症の治療用のセニクリビロック |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020111586A JP2020111586A (ja) | 2020-07-27 |
| JP2020111586A5 true JP2020111586A5 (enExample) | 2020-12-17 |
Family
ID=56614560
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560462A Expired - Fee Related JP6676660B2 (ja) | 2015-02-10 | 2015-09-22 | 線維症の治療用のセニクリビロック |
| JP2020042730A Pending JP2020111586A (ja) | 2015-02-10 | 2020-03-12 | 線維症の治療用のセニクリビロック |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560462A Expired - Fee Related JP6676660B2 (ja) | 2015-02-10 | 2015-09-22 | 線維症の治療用のセニクリビロック |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20180110754A1 (enExample) |
| EP (1) | EP3256124B1 (enExample) |
| JP (2) | JP6676660B2 (enExample) |
| KR (1) | KR20170113596A (enExample) |
| CN (1) | CN107405403B (enExample) |
| AU (1) | AU2015382376B2 (enExample) |
| BR (1) | BR112017016388A2 (enExample) |
| CA (1) | CA2975445A1 (enExample) |
| ES (1) | ES2864767T3 (enExample) |
| HK (1) | HK1247558A1 (enExample) |
| IL (1) | IL253617A0 (enExample) |
| MX (1) | MX2017010277A (enExample) |
| RU (1) | RU2722641C2 (enExample) |
| SG (1) | SG11201706028RA (enExample) |
| WO (1) | WO2016130179A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE539062T1 (de) | 2001-08-08 | 2012-01-15 | Tobira Therapeutics Inc | Bizyklishe verbindung, ihre herstellung und verwendung |
| US10526349B2 (en) | 2014-12-23 | 2020-01-07 | Tobira Therapeutics, Inc. | Process of making cenicriviroc and related analogs |
| BR112018076449A2 (pt) | 2016-06-21 | 2019-04-09 | Tobira Therapeutics, Inc. | cenicriviroc purificado e intermediários purificados para fazer cenicriviroc |
| WO2022235440A1 (en) * | 2021-04-21 | 2022-11-10 | The United States Government As Represented By The Department Of Veterans Affairs | Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2 |
| CN119954974B (zh) * | 2025-04-09 | 2025-07-22 | 四川康德赛医疗科技有限公司 | 一种工程化巨噬细胞，其制备方法及抗纤维化的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2249027A (en) * | 1990-10-23 | 1992-04-29 | Fujisawa Pharmaceutical Co | Use of macrolide compounds for hepatic failure |
| ATE539062T1 (de) | 2001-08-08 | 2012-01-15 | Tobira Therapeutics Inc | Bizyklishe verbindung, ihre herstellung und verwendung |
| US20080031942A1 (en) | 2004-12-03 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Solid Preparation |
| US8148356B2 (en) * | 2005-08-24 | 2012-04-03 | Cumberland Pharmaceuticals, Inc. | Acetylcysteine composition and uses therefor |
| EP2723360B1 (en) * | 2011-06-27 | 2017-05-31 | Université Pierre et Marie Curie (Paris 6) | Ccr2 antagonist peptides |
| JP6263814B2 (ja) * | 2013-03-05 | 2018-01-24 | 国立大学法人 岡山大学 | 細胞死抑制剤及び新規化合物 |
| MX383706B (es) * | 2013-05-15 | 2025-03-14 | Tobira Therapeutics Inc | Composiciones de cenicriviroc y métodos para elaborarlas y usarlas. |
| KR101669124B1 (ko) * | 2013-07-11 | 2016-10-25 | 서울대학교병원 | 인간 배아줄기세포에서 유래된 중간엽 줄기세포를 유효성분으로 함유하는 간섬유화 또는 간경화 예방 및 치료용 조성물 |
-
2015
- 2015-09-22 AU AU2015382376A patent/AU2015382376B2/en not_active Expired - Fee Related
- 2015-09-22 RU RU2017130289A patent/RU2722641C2/ru active
- 2015-09-22 CN CN201580076576.9A patent/CN107405403B/zh not_active Expired - Fee Related
- 2015-09-22 CA CA2975445A patent/CA2975445A1/en not_active Abandoned
- 2015-09-22 EP EP15882259.3A patent/EP3256124B1/en not_active Not-in-force
- 2015-09-22 WO PCT/US2015/051467 patent/WO2016130179A1/en not_active Ceased
- 2015-09-22 SG SG11201706028RA patent/SG11201706028RA/en unknown
- 2015-09-22 KR KR1020177023821A patent/KR20170113596A/ko not_active Ceased
- 2015-09-22 US US15/549,958 patent/US20180110754A1/en not_active Abandoned
- 2015-09-22 JP JP2017560462A patent/JP6676660B2/ja not_active Expired - Fee Related
- 2015-09-22 HK HK18106984.5A patent/HK1247558A1/zh unknown
- 2015-09-22 MX MX2017010277A patent/MX2017010277A/es unknown
- 2015-09-22 BR BR112017016388-8A patent/BR112017016388A2/pt not_active Application Discontinuation
- 2015-09-22 ES ES15882259T patent/ES2864767T3/es active Active
-
2017
- 2017-07-23 IL IL253617A patent/IL253617A0/en unknown
-
2019
- 2019-02-26 US US16/285,867 patent/US20190343806A1/en not_active Abandoned
-
2020
- 2020-03-12 JP JP2020042730A patent/JP2020111586A/ja active Pending
- 2020-06-03 US US16/891,979 patent/US20200360347A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020111586A5 (enExample) | ||
| JP2017105763A5 (enExample) | ||
| SA521422625B1 (ar) | مركبات بنزوثيادايازيبين واستخدامها كمعدلات لحمض الصفراء | |
| JP2022058688A5 (enExample) | ||
| JP2018505218A5 (enExample) | ||
| HRP20170624T1 (hr) | Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti | |
| JP2018168191A5 (enExample) | ||
| JP2018503685A5 (enExample) | ||
| JP2014511374A5 (enExample) | ||
| JP2011506412A5 (enExample) | ||
| AU2014235273A2 (en) | Treatment of psoriatic arthritis using apremilast | |
| HRP20130007T1 (hr) | Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli | |
| JP2016511753A5 (enExample) | ||
| WO2024076670A3 (en) | Tethered heterocyclic inhibitors of kras g12c mutant proteins and uses thereof | |
| JP2015510916A5 (enExample) | ||
| JP2017508817A5 (enExample) | ||
| JP2021073257A5 (enExample) | ||
| RU2017130289A (ru) | Ценикривирок для лечения фиброза | |
| JP2018529666A5 (enExample) | ||
| HRP20241716T1 (hr) | Postupci liječenja promjena u ponašanju | |
| JP2022028975A5 (enExample) | ||
| BR112022004099A2 (pt) | Composto, composição farmacêutica, uso do composto, e, método para o tratamento de uma doença relacionada ao atx | |
| WO2007121545A8 (en) | S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions | |
| RU2014112210A (ru) | Способ увеличения эффективности терапии аутоиммунных заболеваний, таких как ревматоидный артрит | |
| JP2008533021A5 (enExample) |